Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (TAF-PPT): A Multicentre, Prospective, Open-label, Randomized Controlled Trial

Next Previous
Trial Profile

Safety and Efficacy of Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (TAF-PPT): A Multicentre, Prospective, Open-label, Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Hepatitis B vaccine; Immune globulin
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TAF-PPT

Most Recent Events

  • 14 Nov 2023 Status changed to completed, as per results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
  • 14 Nov 2023 Results (April 26, 2021, and June 16, 2023, 119 and 120 intention-to-treat pregnant women were enrolled, and 110 and 112 per-protocol mother-infant dyads in 33GW-DD and 33GW-PPM1 groups completed the study) assessing to compare expected eight versus twelve weeks of tenofovir alafenamide fumarate therapy to prevent HBV-MTCT, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
  • 26 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top